Zhejiang Huahai Pharmaceutical (600521.SH): Mesalazine enteric-coated tablets obtain drug registration certificate.

17:02 03/04/2026

Huahai Pharmaceutical (600521.SH) announced that the company has recently received the "Drug Registration Certificate" for the mesalazine enteric-coated tablets issued by the National Medical Products Administration. Mesalazine enteric-coated tablets are used for the treatment of: 1. Ulcerative colitis, including treatment during acute attacks and maintenance therapy to prevent recurrence; 2. Treatment during acute attacks of Crohn's disease.

Zhejiang Huahai Pharmaceutical (600521.SH) announced that the company has recently received the "Drug Registration Certificate" for Mesalazine Enteric-coated Tablets issued by the National Medical Products Administration. Mesalazine Enteric-coated Tablets are used for: 1. Treatment of ulcerative colitis, including treatment during acute attacks and maintenance therapy to prevent relapse; 2. Treatment of acute attacks of Crohn's disease.

Zhixiang Jintai (688443.SH) plans to launch a restricted stock incentive plan in 2026.

Wuchan Zhongda Group plans to repurchase shares worth 200 million to 400 million yuan.

WELLE Environmental Group (300190.SZ) has won the bidding for a sewage treatment project worth 44.88 million yuan.

Zhixiang Jintai (688443.SH) plans to launch a restricted stock incentive plan in 2026.

Wuchan Zhongda Group plans to repurchase shares worth 200 million to 400 million yuan.

WELLE Environmental Group (300190.SZ) has won the bidding for a sewage treatment project worth 44.88 million yuan.